Armata Pharmaceuticals, Inc. (ARMP)
NYSEAMERICAN: ARMP · Real-Time Price · USD
2.350
-0.010 (-0.42%)
Nov 4, 2024, 3:51 PM EST - Market closed

Company Description

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide.

It develops its products using its proprietary bacteriophage-based technology. The company’s product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.

It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents.

The company is headquartered in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.

Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals logo
Country United States
Industry Biotechnology
Sector Healthcare
Employees 66
CEO Deborah Birx

Contact Details

Address:
5005 McConnell Avenue
Los Angeles, California 90066
United States
Phone 310 665 2928
Website armatapharma.com

Stock Details

Ticker Symbol ARMP
Exchange NYSEAMERICAN
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000921114
CUSIP Number 04216R102
ISIN Number US04216R1023
Employer ID 91-1549568
SIC Code 2836

Key Executives

Name Position
Dr. Deborah L. Birx M.D. Chief Executive Officer and Director
Dr. Mina Pastagia M.D., MS Chief Medical Officer
David House Senior Vice President of Finance and Principal Financial Officer
Peter Hubbard Vice President of Operations
Dr. Pierre Kyme Ph.D. Chief Business Officer

Latest SEC Filings

Date Type Title
Oct 3, 2024 8-K Current Report
Sep 26, 2024 8-K Current Report
Aug 26, 2024 8-K Current Report
Aug 15, 2024 8-K Current Report
Aug 13, 2024 10-Q Quarterly Report
Aug 13, 2024 8-K Current Report
Jul 25, 2024 8-K Current Report
Jun 14, 2024 8-K Current Report
May 7, 2024 10-Q Quarterly Report
May 7, 2024 8-K Current Report